All news

AbbVie flags $216M IPR&D charge, cuts EPS guidance

Alpha Vantage · GuruFocus · · AI-summarised by FinFlash

AbbVie disclosed a pre-tax charge of $216 million tied to acquired in-process research and development and milestone payments, lowering its third-quarter and full-year EPS guidance. The company retains a strong GF Score and an attractive dividend yield, though an 85% payout ratio raises questions about dividend sustainability. GF Value™ indicates the stock is modestly overvalued, while insider selling and a weaker financial strength rating point to a cautious investor outlook.

Read original source

ABBV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.